Metastatic Melanoma and Merkel Cell Carcinoma

1 clinical trials · Condition

Record	Firm	Date
A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma (NCT01652547)	Novartis Pharmaceuticals	2012-11-01

Every clearance here is in the API, with alerts when new ones post.